FDA Places Clinical Hold On Atara Biotherapeutics' Two Cell Therapy Programs
1. FDA placed a clinical hold on Atara's ATRA IND applications. 2. Enrollment paused for EBVALLO and ATA3219 clinical studies. 3. GMP compliance issues affect drug production but not all manufacturers. 4. Atara risks suspending CAR-T programs without funding by Q1 2025. 5. Stock down 4.09%, reflecting investor concerns over development setbacks.